Publications en collaboration avec des chercheurs de University of California, San Francisco (10)

2024

  1. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells

    Frontiers in Oncology, Vol. 11

  2. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    The Lancet, Vol. 397, Núm. 10292, pp. 2361-2371

  3. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

    Journal of Hematology and Oncology

2020

  1. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

    Blood Advances, Vol. 4, Núm. 14, pp. 3295-3301

  2. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements

    PLoS ONE, Vol. 15, Núm. 8 August

2014

  1. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database

    Nature Genetics, Vol. 46, Núm. 2, pp. 107-115